(KMPH) - Earnings & Price History

KMPH: - 3.7085, $56.71M, -0.09 (-2.41%)

Sector: Healthcare - Industry: Biotechnology

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its advanced product candidate is KP201/APAP, which consists of KP201 prodrug of hydrocodone formulated in combination with acetaminophen (APAP). The company is also developing KP201/APAP as an immediate release (IR) product candidate for the treatment of acute pain, as well as engages in designing KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse. The company is also involved in developing KP201/IR (APAP-free), an IR formulation of KP201 without APAP for the short-term management of acute pain; KP511/ER, a prodrug of hydromorphone for the management of pain; KP415, a prodrug of methylphenidate for the treatment of attention deficit hyperactivity disorders; KP606/IR, an IR abuse-deterrent opioid product for the managemen

Past KMPH reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume

Login | Register
Sunday Jun 16, 2019   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR


index chart
index color